12. Myelodysplastisk syndrom/neoplasi (MDS) og kronisk myelomonocytt-leukemi (KMML)

Antun, A. G., Gleason, S., Arellano, M., Langston, A. A., McLemore, M. L., Gaddh, M., el Rassi, F., Bernal-Mizrachi, L., ... Khoury, H. J. (2013). Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. Cancer, 119(21), 3784-7.

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391-405.

Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H. M., Wang, S. A., Bagg, A., ... Tefferi, A. (2022). International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 140(11), 1200-1228.

Armand, P., Kim, H. T., Rhodes, J., Sainvil, M. M., Cutler, C., Ho, V. T., Koreth, J., Alyea, E. P., ... Antin, J. H. (2011). Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biology of Blood and Marrow Transplantation, 17(6), 852-60.

Azizi, A., Ediriwickrema, A., Dutta, R., Patel, S. A., Shomali, W., Medeiros, B., Iberri, D., Gotlib, J., ... Zhang, T. (2020). Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leukemia and Lymphoma, 61(11), 2700-2707.

Baliakas, P., Tesi, B., Wartiovaara-Kautto, U., Stray-Pedersen, A., Friis, L. S., Dybedal, I., Hovland, R., Jahnukainen, K., ... Andersen, M. K. (2019). Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up. HemaSphere, 3(6), e321.

Ball, B. J., Famulare, C. A., Stein, E. M., Tallman, M. S., Derkach, A., Roshal, M., Gill, S. I., Manning, B. M., ... Goldberg, A. D. (2020). Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood advances, 4(13), 2866-2870.

Basood, M., Oster, H. S., & Mittelman, M. (2018). Thrombocytopenia in Patients with Myelodysplastic Syndromes: Still an Unsolved Problem. Mediterranean journal of hematology and infectious diseases, 10(1), e2018046.

Bazinet, A., Darbaniyan, F., Jabbour, E., Montalban-Bravo, G., Ohanian, M., Chien, K., Kadia, T., Takahashi, K., ... Garcia-Manero, G. (2022). Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. The Lancet. Haematology, 9(10), e756-e765.

Beelen, D. W., Stelljes, M., Reményi, P., Wagner-Drouet, E. M., Dreger, P., Bethge, W., Ciceri, F., Stölzel, F., ... Markiewicz, M. (2022). Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial. American journal of hematology, 97(8), 1023-1034.

Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., ... Papaemmanuil, E. (2020). Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature medicine, 26(10), 1549-1556.

Bernard, E., Tuechler, H., Greenberg, P. L., Hasserjian, R. P., Arango Ossa, J. E., Nannya, Y., Devlin, S. M., Creignou, M., ... Papaemmanuil, E. (2022). Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evidence, 1(7), EVIDoa2200008.

Bewersdorf, J. P., Derkach, A., Gowda, L., Menghrajani, K., DeWolf, S., Ruiz, J. D., Ponce, D. M., Shaffer, B. C., ... Stahl, M. (2021). Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia and Lymphoma, 62(14), 3394-3401.

Cremers, E. M., Westers, T. M., Alhan, C., Cali, C., Visser-Wisselaar, H. A., Chitu, D. A., van der Velden, V. H., Te Marvelde, J. G., ... van de Loosdrecht, A. A. (2017). Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes. Haematologica, 102(2), 320-326.

Damaj, G., Duhamel, A., Robin, M., Beguin, Y., Michallet, M., Mohty, M., Vigouroux, S., Bories, P., ... Yakoub-Agha, I. (2012). Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. Journal of Clinical Oncology, 30(36), 4533-40.

de Witte, T., Bowen, D., Robin, M., Malcovati, L., Niederwieser, D., Yakoub-Agha, I., Mufti, G. J., Fenaux, P., ... Kroger, N. (2017). Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood, 129(13), 1753-1762.

Denzlinger, C., Bowen, D., Benz, D., Gelly, K., Brugger, W., & Kanz, L. (2000). Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia. British Journal of Haematology, 108(1), 93-5.

DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., ... Letai, A. (2019). Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood, 133(1), 7-17.

Elena, C., Galli, A., Such, E., Meggendorfer, M., Germing, U., Rizzo, E., Cervera, J., Molteni, E., ... Cazzola, M. (2016). Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood, 128(10), 1408-17.

Fain, O., Hamidou, M., Cacoub, P., Godeau, B., Wechsler, B., Pariès, J., Stirnemann, J., Morin, A. S., ... Guillevin, L. (2007). Vasculitides associated with malignancies: analysis of sixty patients. Arthritis and rheumatism, 57(8), 1473-80.

Falini, B., & Martelli, M. P. (2023). Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia. American journal of hematology, 98(3), 481-492.

Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G., Mittelman, M., Muus, P., Te Boekhorst, P., ... Hellstrom-Lindberg, E. (2011). A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood, 118(14), 3765-76.

Fenaux, P., Platzbecker, U., Mufti, G. J., Garcia-Manero, G., Buckstein, R., Santini, V., Díez-Campelo, M., Finelli, C., ... List, A. F. (2020). Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. New England Journal of Medicine, 382(2), 140-151.

Fenaux, P., Santini, V., Spiriti, M. A. A., Giagounidis, A., Schlag, R., Radinoff, A., Gercheva-Kyuchukova, L., Anagnostopoulos, A., ... Platzbecker, U. (2018). A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-alpha in anemic patients with low-risk MDS. Leukemia, 32(12), 2648-2658.

Feng, R., Bhatt, V. R., Fu, K., Pirruccello, S., & Yuan, J. (2018). Application of immunophenotypic analysis in distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Cytometry. Part B, Clinical cytometry, 94(6), 901-909.

Fink, E. C., & Ebert, B. L. (2015). The novel mechanism of lenalidomide activity. Blood, 126(21), 2366-9.

Garcia-Manero, G., Mufti, G. J., Fenaux, P., Buckstein, R., Santini, V., Díez-Campelo, M., Finelli, C., Ilhan, O., ... Komrokji, R. S. (2022). Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood, 139(4), 624-629.

Gattermann, N., Finelli, C., Porta, M. D., Fenaux, P., Ganser, A., Guerci-Bresler, A., Schmid, M., Taylor, K., ... Rose, C. (2010). Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leukemia Research, 34(9), 1143-50.

Gerds, A. T., Gooley, T. A., Estey, E. H., Appelbaum, F. R., Deeg, H. J., & Scott, B. L. (2012). Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biology of Blood and Marrow Transplantation, 18(8), 1211-8.

Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., ... Haase, D. (2012). Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 120(12), 2454-65.

Grob, T., Al Hinai, A. S. A., Sanders, M. A., Kavelaars, F. G., Rijken, M., Gradowska, P. L., Biemond, B. J., Breems, D. A., ... Valk, P. J. M. (2022). Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 139(15), 2347-2354.

Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., ... Bejar, R. (2019). TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 33(7), 1747-1758.

Haider, M., Al Ali, N., Padron, E., Epling-Burnette, P., Lancet, J., List, A., & Komrokji, R. (2016). Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome. Clinical lymphoma, myeloma & leukemia, 16 Suppl, S44-8.

Hasserjian, R. P., Orazi, A., Orfao, A., Rozman, M., & Wang, S. A. (2023). The International Consensus Classification of myelodysplastic syndromes and related entities. Virchows Archiv : an international journal of pathology, 482(1), 39-51.

Hast, R., Hellström-Lindberg, E., Ohm, L., Björkholm, M., Celsing, F., Dahl, I. M., Dybedal, I., Gahrton, G., ... Bernell, P. (2003). No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leukemia, 17(9), 1827-33.

Hellström-Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I. M., Dybedal, I., Grimfors, G., Hesse-Sundin, E., ... Wisloff, F. (2003). A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology, 120(6), 1037-46.

Hochman, M. J., & DeZern, A. E. (2022). Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?. The Lancet. Haematology, 9(7), e523-e534.

Itzykson, R., Fenaux, P., Bowen, D., Cross, N. C. P., Cortes, J., De Witte, T., Germing, U., Onida, F., ... Malcovati, L. (2018). Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet. HemaSphere, 2(6), e150.

Itzykson, R., Kosmider, O., Renneville, A., Gelsi-Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Adès, L., ... Solary, E. (2013). Prognostic score including gene mutations in chronic myelomonocytic leukemia. Journal of Clinical Oncology, 31(19), 2428-36.

Jabbour, E. J., Garcia-Manero, G., Strati, P., Mishra, A., Al Ali, N. H., Padron, E., Lancet, J., Kadia, T., ... Komrokji, R. S. (2015). Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer, 121(6), 876-82.

Jachiet, V., Fenaux, P., Sevoyan, A., Hakobyan, Y., Ades, L., Fain, O., Mekinian, A., & on behalf of the MINHEMON and GFM (2021). Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes. Hemato, 2(2), 329-346.

Jädersten, M., Boriskina, K., Lindholm, C., Weström, S., Cavelier, L., Hellström-Lindberg, E., Mielke, S., & Tobiasson, M. (2022). Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation. Leukemia and Lymphoma, 63(3), 755-758.

Jädersten, M., Montgomery, S. M., Dybedal, I., Porwit-MacDonald, A., & Hellström-Lindberg, E. (2005). Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood, 106(3), 803-11.

Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., ... Mufti, G. J. (2011). TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. Journal of Clinical Oncology, 29(15), 1971-9.

Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., ... Ebert, B. L. (2014). Age-related clonal hematopoiesis associated with adverse outcomes. New England Journal of Medicine, 371(26), 2488-98.

Jones, P. A., & Taylor, S. M. (1980). Cellular differentiation, cytidine analogs and DNA methylation. Cell, 20(1), 85-93.

Kadia, T. M., Borthakur, G., Garcia-Manero, G., Faderl, S., Jabbour, E., Estrov, Z., York, S., Huang, X., ... Ravandi, F. (2012). Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. British Journal of Haematology, 157(3), 312-20.

Kern, W., Westers, T. M., Bellos, F., Bene, M. C., Bettelheim, P., Brodersen, L. E., Burbury, K., Chu, S. C., ... van de Loosdrecht, A. (2023). Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group. Cytometry. Part B, Clinical cytometry, 104(1), 51-65.

Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., ... Hochhaus, A. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia, 36(7), 1703-1719.

Knipp, S., Hildebrand, B., Kündgen, A., Giagounidis, A., Kobbe, G., Haas, R., Aul, C., Gattermann, N., & Germing, U. (2007). Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer, 110(2), 345-52.

Kröger, N., Sockel, K., Wolschke, C., Bethge, W., Schlenk, R. F., Wolf, D., Stadler, M., Kobbe, G., ... Platzbecker, U. (2021). Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). Journal of Clinical Oncology, 39(30), 3318-3327.

Lee, Y. G., Kim, I., Yoon, S. S., Park, S., Cheong, J. W., Min, Y. H., Lee, J. O., Bang, S. M., ... Kim, H. J. (2013). Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. British Journal of Haematology, 161(3), 339-47.

Lian, X. Y., Zhang, Z. H., Deng, Z. Q., He, P. F., Yao, D. M., Xu, Z. J., Wen, X. M., Yang, L., ... Qian, J. (2016). Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis. PLoS One, 11(11), e0165948.

Liang, Q., Zhao, J., Zhang, L., Gao, Z., Pan, H., Fang, L., & Shi, J. (2022). Association of systemic inflammatory and autoimmune manifestations with myelodysplastic syndromes: A systematic review and meta-analysis. Medicine (Baltimore), 101(46), e31427.

Liu, B., Guo, Y., Deng, L., Qiao, Y., & Jian, J. (2020). The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis. Hematology, 25(1), 414-423.

Mekinian, A., Dervin, G., Lapidus, N., Kahn, J. E., Terriou, L., Liozon, E., Grignano, E., Piette, J. C., ... Fain, O. (2017). Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. Autoimmunity reviews, 16(9), 903-910.

Mekinian, A., Grignano, E., Braun, T., Decaux, O., Liozon, E., Costedoat-Chalumeau, N., Kahn, J. E., Hamidou, M., ... Fain, O. (2016). Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford), 55(2), 291-300.

Meng, F., Chen, X., Yu, S., Ren, X., Liu, Z., Fu, R., & Li, L. (2020). Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis. Frontiers in oncology, 10, 582686.

Moreno Berggren, D., Kjellander, M., Backlund, E., Engvall, M., Garelius, H., Lorenz, F., Nilsson, L., Rasmussen, B., ... Ejerblad, E. (2021). Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study. British Journal of Haematology, 192(3), 474-483.

Nilsson-Ehle, H., Birgegard, G., Samuelsson, J., Antunovic, P., Astermark, J., Garelius, H., Engstrom, L. M., Kjeldsen, L., ... Hellstrom-Lindberg, E. (2011). Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of >/=120 g/L with darbepoetin alfa +/- filgrastim or erythrocyte transfusions. European Journal of Haematology, 87(3), 244-52.

Oelschlaegel, U., Oelschlaeger, L., von Bonin, M., Kramer, M., Sockel, K., Mohr, B., Wagenfuehr, L., Kroschinsky, F., ... Platzbecker, U. (2023). Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact. Cytometry. Part B, Clinical cytometry, 104(2), 141-150.

Oliva, E. N., Alati, C., Santini, V., Poloni, A., Molteni, A., Niscola, P., Salvi, F., Sanpaolo, G., ... Latagliata, R. (2017). Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. The Lancet. Haematology, 4(3), e127-e136.

Osman, A. E. W. G. (2021). When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?. Hematology / the Education Program of the American Society of Hematology, 2021(1), 399-404.

Park, S. J., Han, C. W., Lee, J. H., Eom, H. S., Lee, S. H., Jeong, D. C., & Lim, J. H. (2003). Cyclosporine A in the treatment of a patient with immune thrombocytopenia accompanied by myelodysplastic syndrome and nephrotic syndrome. Acta Haematologica, 110(1), 36-40.

Patnaik, M. M., & Tefferi, A. (2022). Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. American journal of hematology, 97(3), 352-372.

Platzbecker, U. (2019). Treatment of MDS. Blood, 133(10), 1096-1107.

Pleyer, L., Leisch, M., Kourakli, A., Padron, E., Maciejewski, J. P., Xicoy Cirici, B., Kaivers, J., Ungerstedt, J., ... Greil, R. (2021). Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. The Lancet. Haematology, 8(2), e135-e148.

Porwit, A., Béné, M. C., Duetz, C., Matarraz, S., Oelschlaegel, U., Westers, T. M., Wagner-Ballon, O., Kordasti, S., ... van de Loosdrecht, A. A. (2023). Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group. Cytometry. Part B, Clinical cytometry, 104(1), 27-50.

Prébet, T., Gore, S. D., Esterni, B., Gardin, C., Itzykson, R., Thepot, S., Dreyfus, F., Rauzy, O. B., ... Vey, N. (2011). Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. Journal of Clinical Oncology, 29(24), 3322-7.

Robin, M., de Wreede, L. C., Padron, E., Bakunina, K., Fenaux, P., Koster, L., Nazha, A., Beelen, D. W., ... Itzykson, R. (2022). Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. Blood, 140(12), 1408-1418.

Robin, M., Porcher, R., Adès, L., Raffoux, E., Michallet, M., François, S., Cahn, J. Y., Delmer, A., ... Socié, G. (2015). HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. Leukemia, 29(7), 1496-501.

Saft, L., Karimi, M., Ghaderi, M., Matolcsy, A., Mufti, G. J., Kulasekararaj, A., Gohring, G., Giagounidis, A., ... Hellstrom-Lindberg, E. (2014). p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica, 99(6), 1041-9.

Sandes, A. F., Kerbauy, D. M., Matarraz, S., Chauffaille Mde, L., López, A., Orfao, A., & Yamamoto, M. (2013). Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes. Cytometry. Part B, Clinical cytometry, 84(3), 157-66.

Sekeres, M. A., & Taylor, J. (2022). Diagnosis and Treatment of Myelodysplastic Syndromes: A Review. JAMA : the journal of the American Medical Association, 328(9), 872-880.

Seymour, J. F., Fenaux, P., Silverman, L. R., Mufti, G. J., Hellström-Lindberg, E., Santini, V., List, A. F., Gore, S. D., ... Beach, C. L. (2010). . Critical Reviews in Oncology/Hematology, 76(3), 218-27.

Shimoni, A., Robin, M., Iacobelli, S., Beelen, D., Mufti, G. J., Ciceri, F., Bethge, W., Volin, L., ... Yakoub-Agha, I. (2021). Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. British Journal of Haematology, 195(3), 417-428.

Silverman, L. R., Fenaux, P., Mufti, G. J., Santini, V., Hellström-Lindberg, E., Gattermann, N., Sanz, G., List, A. F., ... Seymour, J. F. (2011). Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer, 117(12), 2697-702.

Sorror, M. L. (2013). How I assess comorbidities before hematopoietic cell transplantation. Blood, 121(15), 2854-63.

Stahl, M., DeVeaux, M., de Witte, T., Neukirchen, J., Sekeres, M. A., Brunner, A. M., Roboz, G. J., Steensma, D. P., ... Zeidan, A. M. (2018). The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood advances, 2(14), 1765-1772.

Stratmann, J., van Kann, E., Rummelt, C., Koschade, S., Röllig, C., Lübbert, M., Schaich, M., Parmentier, S., ... Shaid, S. (2019). Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure. Leukemia Research, 85, 106192.

Such, E., Germing, U., Malcovati, L., Cervera, J., Kuendgen, A., Della Porta, M. G., Nomdedeu, B., Arenillas, L., ... Sanz, G. (2013). Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood, 121(15), 3005-15.

Swerdlow, S. H., Campo, E., Harris, N. L., Jaffe, E. S., Pileri, S. A., Stein, H., ... Thiele, J. (2017). WHO classification of tumours of haematopoietic and lymphoid tissue. IARC.

Symeonidis, A., van Biezen, A., de Wreede, L., Piciocchi, A., Finke, J., Beelen, D., Bornhauser, M., Cornelissen, J., ... Kroger, N. (2015). Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. British Journal of Haematology, 171(2), 239-246.

Valent, P., Orazi, A., Steensma, D. P., Ebert, B. L., Haase, D., Malcovati, L., van de Loosdrecht, A. A., Haferlach, T., ... Bennett, J. M. (2017). Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget, 8(43), 73483-73500.

Van Rhee, F., & Abela, M. (1991). Coombs negative haemolytic anaemia responding to intravenous immunoglobulins in a patient with myelodysplastic syndrome. Clinical and laboratory haematology, 13(1), 99-101.

Vittayawacharin, P., Kongtim, P., & Ciurea, S. O. (2023). Allogeneic stem cell transplantation for patients with myelodysplastic syndromes. American journal of hematology, 98(2), 322-337.

Vo, C. D., Myhre, A. E., Abrahamsen, I. W., Remberger, M., Mattsson, J., Fløisand, Y., Grønvold, B. C. L., Tjønnfjord, G. E., ... Gedde-Dahl, T. (2023). Allogen stamcelletransplantasjon hos voksne 2015–21. Tidsskrift for den Norske legeforening, 143(4)

Walter, W., Müller, H., Haferlach, C., Baer, C., Hutter, S., Nadarajah, N., Kern, W., Haferlach, T., & Meggendorfer, M. (2021). Copy-Neutral Loss-of-Heterozygosity Adds Diagnostic and Prognostic Information to the Molecular Profiling of Hematological Malignancies. Blood, 138(Suppl 1), 2228.

Wang, K., Shao, Y., Li, C., Bao, J., Zhu, W., & Zhou, Y. (2022). Effect of thrombopoietin receptor agonist on health-related quality of life and platelet transfusion burden for patients with myelodysplastic syndromes: a systematic review and meta-analysis. Annals of hematology, 101(10), 2219-2229.

Wang, W., & Khoury, J. D. (2023). Where diagnosis for myelodysplastic neoplasms (MDS) stands today and where it will go: The role of flow cytometry in evaluation of MDS. Cytometry. Part B, Clinical cytometry, 104(1), 12-14.

Wedge, E., Hansen, J. W., Dybedal, I., Creignou, M., Ejerblad, E., Lorenz, F., Werlenius, O., Ungerstedt, J., ... Friis, L. S. (2021). Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population. Transplantation and cellular therapy, 27(12), 991.e1-991.e9.

Wei, A. H., Strickland, S. A. ,. J., Hou, J. Z., Fiedler, W., Lin, T. L., Walter, R. B., Enjeti, A., Tiong, I. S., ... Roboz, G. J. (2019). Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology, 37(15), 1277-1284.

Weinberg, O. K., Siddon, A., Madanat, Y. F., Gagan, J., Arber, D. A., Dal Cin, P., Narayanan, D., Ouseph, M. M., ... Hasserjian, R. P. (2022). TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood advances, 6(9), 2847-2853.

Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O'Laughlin, M., Fulton, R. S., Wilson, R. K., Baty, J. D., ... Ley, T. J. (2016). TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 375(21), 2023-2036.

Whittle, A. M., Feyler, S., & Bowen, D. T. (2013). Durable second complete remissions with oral melphalan in hypocellular Acute Myeloid Leukemia and Refractory Anemia with Excess Blast with normal karyotype relapsing after intensive chemotherapy. Leukemia research reports, 2(1), 9-11.

Yahng, S. A., Kim, M., Kim, T. M., Jeon, Y. W., Yoon, J. H., Shin, S. H., Lee, S. E., Eom, K. S., ... Kim, Y. J. (2017). Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts. Oncotarget, 8(7), 12342-12354.

Yang, T. T., Song, X. L., Zhao, Y. M., Ye, B. D., Luo, Y., Xiao, H. W., Chen, Y., Fu, H. R., ... Shi, J. M. (2022). Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients. Annals of hematology, 101(12), 2731-2741.

Zahid, M. F., Barraco, D., Lasho, T. L., Finke, C., Ketterling, R. P., Gangat, N., Hanson, C. A., Tefferi, A., & Patnaik, M. M. (2017). Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leukemia and Lymphoma, 58(6), 1488-1493.

Zeidan, A. M., Platzbecker, U., Bewersdorf, J. P., Stahl, M., Adès, L., Borate, U., Bowen, D., Buckstein, R., ... Fenaux, P. (2023). Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood, 141(17), 2047-2061.

Zhang, Y., Wu, J., Qin, T., Xu, Z., Qu, S., Pan, L., Li, B., Wang, H., ... Xiao, Z. (2022). Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms. Leukemia, 36(12), 2875-2882.